The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Donepezil Hydrochloride (E2020) and Other Acetylcholinesterase Inhibitors
Abstract
A wide range of evidence shows that acetylcholinesterase (AChE) inhibitors can interfere with the progression of Alzheimer's disease (AD). The successful development of these compounds was based on a well-accepted theory that the decline in cognitive and mental functions associated with AD is related to the loss of cortical cholinergic neurotransmission. The earliest known AChE inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of Alzheimer's patients. However, clinical studies show that physostigmine has poor oral activity, brain penetration and pharmacokinetic parameters while tacrine has hepatotoxic liability. Studies were then focused on finding a new type of acetylcholinesterase inhibitor that would overcome the disadvantages of these two compounds. Donepezil hydrochloride inaugurates a new class of AChE inhibitors with longer and more selective action with manageable adverse effects. Currently, there are about 19 new Alzheimer's drugs in various phases of clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholinergic Basis for Alzheimer Therapy
(1991) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4899-6738-1 · Cited by 181
Alzheimer's disease : biology, diagnosis, and therapeutics
Iqbal, K., & Disorders, R. (1996) · SDÜ Bilgi Merkezi · Cited by 153
Alzheimer's disease — from molecular biology to therapy
Mayer, R. J. (1993) · Trends in biotechnology · doi:10.1016/0167-7799(93)90014-z · Cited by 67
Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases: Volume 1
(1990) · Advances in behavioral biology · doi:10.1007/978-1-4684-5844-2 · Cited by 63
Cited by
Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands
Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M. S., Gary, E. N., Love, J., Franklin, M. C., & Height, J. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300871x · Cited by 1,356
Prescribed drugs containing nitrogen heterocycles: an overview
Heravi, M. M., & Zadsirjan, V. (2020) · RSC Advances · doi:10.1039/d0ra09198g · Cited by 1,194
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Acetylcholinesterase in Alzheimer's disease
Talesa, V. N. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00309-8 · Cited by 450
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
Zemek, F., Drtinova, L., Nepovimova, E., Sepsova, V., Korabecny, J., Klimes, J., & Kuca, K. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.914168 · Cited by 299
Metadata
- Authors
- Sugimoto, H., Yamanish, Y., Iimura, Y., & Kawakami, Y.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2000-03-01
- Volume
- 7
- Issue
- 3
- Pages
- 303-339
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2097802864
- Cited by
- 324
- References
- 4
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Donepezil Hydrochloride (E2020) and Other Acetylcholinesterase Inhibitors. https://app.cochat.ai/papers/10.2174/0929867003375191
- The paper
- Sugimoto, H., Yamanish, Y., Iimura, Y., & Kawakami, Y. (2000). Donepezil Hydrochloride (E2020) and Other Acetylcholinesterase Inhibitors. Current Medicinal Chemistry. https://doi.org/10.2174/0929867003375191
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.